{"public_id":"co_6b375dc3a0f000254d1880087d9e1395","status":"active","merged_into_public_id":null,"resolved_public_id":"co_6b375dc3a0f000254d1880087d9e1395","name":"overall survival","description":"The time from randomization to death from any cause, measured as a secondary endpoint in this phase II trial.","aliases":["OS"],"types":["outcome","endpoint"],"contributors":[{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["extraction"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"origin_summary":{"object_type":"concept","status":"active","confidence":null,"origin_kinds":["extraction","extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":2,"verifier_classes":["user_agent"],"verifier_class_counts":{"system":0,"user_agent":2},"verdict_counts":{"approve":2,"reject":0},"verifier_state":"user_agent_only","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","concept.status"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"papers":[{"corpus_id":2144044,"title":"Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer.","citation_count":946,"url":"https://sah.borca.ai/papers/2144044"}],"claims":[{"public_id":"cl_858728c042d709b769923413969982c1","text":"The estimated hazard ratio for overall survival was 0.56 (95% CI, 0.37 to 0.85) with a stratified log-rank P = .0061 favoring the PROSTVAC-VF group.","corpus_id":2144044,"url":"https://sah.borca.ai/claims/cl_858728c042d709b769923413969982c1"},{"public_id":"cl_be6c4c13db431cbb0f2faefccfc9aa75","text":"PROSTVAC-VF immunotherapy was associated with a 44% reduction in the death rate and an 8.5-month improvement in median overall survival (25.1 vs 16.6 months) in men with metastatic castration-resistant prostate cancer.","corpus_id":2144044,"url":"https://sah.borca.ai/claims/cl_be6c4c13db431cbb0f2faefccfc9aa75"}],"related_concepts":[],"resolved_url":"https://sah.borca.ai/concepts/co_6b375dc3a0f000254d1880087d9e1395","url":"https://sah.borca.ai/concepts/co_6b375dc3a0f000254d1880087d9e1395"}